Cognitive-behavioral and pharmacological interventions for premenstrual syndrome or premenstrual dysphoric disorder: A meta-analysis

Journal of Clinical Psychology in Medical Settings

Volumn 19, Issue 3, 2012, Pages 308-319

  Kleinstäuber, Maria ^a   Witthöft, Michael ^a   Hiller, Wolfgang ^a  

^a JOHANNES GUTENBERG UNIVERSITY   (Germany)

Author keywords

Cognitive behavioral interventions; Keywords Premenstrual syndrome; Premenstrual dysphoric disorder; Selective serotonin reuptake inhibitor

Indexed keywords

ALPRAZOLAM; AMFEBUTAMONE; ANXIOLYTIC AGENT; DESIPRAMINE; ESCITALOPRAM; FLUOXETINE; HYPERICUM PERFORATUM EXTRACT; MOOD STABILIZER; NEUROLEPTIC AGENT; PAROXETINE; PROGESTERONE; SEROTONIN UPTAKE INHIBITOR; SERTRALINE; TRANQUILIZER; VENLAFAXINE;

ARTICLE; COGNITIVE THERAPY; DATA EXTRACTION; DRUG EFFICACY; EFFECT SIZE; FOLLOW UP; HUMAN; HYPERICUM PERFORATUM; META ANALYSIS; PREMENSTRUAL DYSPHORIC DISORDER; PREMENSTRUAL SYNDROME; PRIORITY JOURNAL; PSYCHOPHARMACOTHERAPY; PUBLISHING;

COGNITIVE THERAPY; COMBINED MODALITY THERAPY; FEMALE; HUMANS; PREMENSTRUAL SYNDROME; SEROTONIN UPTAKE INHIBITORS; TREATMENT OUTCOME;

EID: 84867283491     PISSN: 10689583     EISSN: 15733572     Source Type: Journal    
DOI: 10.1007/s10880-012-9299-y     Document Type: Article

References (62)

1. American College of Obstetricians and Gynecologists. (2000a). Premenstrual syndrome. Washington, DC: National Guideline Clearinghouse. American College of Obstetricians and Gynecologists. (2000b). Clinical management guidelines for obstetrician-gynecologists: Premenstrual syndrome. ACOG Practice Bulletin, 15, 3-8.
2. American Psychiatric Association. (1987). Diagnostic and statistical manual of mental disorders (3rd ed., rev.). Washington, DC: American Psychiatric Press.
3. American Psychiatric Association. (1994). Diagnostic and statistical manual for mental disorders (DSM IV). Washington, DC: American Psychiatric Press.
4. Angst, J., Sellaro, R., Merikangas, K. R., & Endicott, J. (2001). The epidemiology of perimenstrual psychological symptoms. Acta Psychiatrica Scandinavica, 104, 110-116.
5. Arredondo-Soberon, F., Freeman, E. W., & Sondheimer, S. J. (1997). Relationship and response of food cravings and depression to sertraline in patients with premenstrual syndrome. Fertility and Sterility, 68(Suppl. 1), S27-S28.
6. Becker, B. J. (1988). Synthesizing standardized mean-change measures. British Journal of Mathematical and Statistical Psychology, 41, 257-278.
7. Bhatia, S. C., & Bhatia, S. K. (2002). Diagnosis and treatment of premenstrual dysphoric disorder. American Family Physician, 66, 1239-1248.
8. Blake, F., Salkovskis, P., Gath, D., Day, A., & Garrod, A. (1998). Cognitive therapy for premenstrual syndrome: A controlled trial. Journal of Psychosomatic Research, 45, 307-318.
9. Brown, J., O'Brien, P. M. S., Marjoribanks, J., & Wyatt, K. (2009). Selective serotonin reuptake inhibitors for premenstrual syndrome. Cochrane Database of Systematic Reviews, 2009, Art. No.: CD001396. doi:10.1002/14651858. CD001396.pub2.
10. Busse, J. W., Montori, V. M., Krasnik, C., Patelis-Siotis, I., & Guyatt, G. H. (2008). Psychological intervention for premenstrual syndrome: A meta-analysis of randomized controlled trials. Psychotherapy and Psychosomatics, 78, 6-15.
11. Campbell, E. M., Peterkin, D., O'Grady, K., & Sanson-Fisher, R. (1997). Premenstrual symptoms in general practice: Prevalence and treatment. Journal of Reproductive Medicine, 42, 637-646.
12. Cohen, J. (1977). Statistical power analysis for the behavioral sciences (Rev. ed.). New York: Academic Press.
13. Crnobaric, C., Jasovic-Gasic, M., Milovanovic, S., & Miljevic, C. (1998). Treatment of premenstrual dysphoric disorder with fluoxetine during the luteal phase. European Psychiatry, 13(Suppl. 4), 251s.
14. Cuijpers, P., Van Straten, A., Bohlmeijer, E., Hollon, S. D., & Andersson, G. (2010). The effects of psychotherapy for adult depression are overestimated: A meta-analysis of study quality and effect size. Psychological Medicine, 40, 211-223.
15. Cunningham, J., Yonkers, K. A., O'Brien, S., & Eriksson, E. (2009). Update on research and treatment of premenstrual dysphoric disorder. Harvard Review of Psychiatry, 17, 120-137.
16. Endicott, J., & Halbreich, U. (1982). Retrospective reports of depressive premenstrual changes: Factors affecting confirmation by daily ratings. Psychopharmacology Bulletin, 18, 109-112.
17. Eriksson, E., Ekman, A., Sinclair, S., Sörvik, K., Ysander, C., Mattson, U. B., et al. (2008). Escitalopram administered in the luteal phase exerts a marked and dose-dependent effect in premenstrual dysphoric disorder. Journal of Clinical Psychopharmacology, 28, 195-202.
18. Freeman, E. W. (2003). Premenstrual syndrome and premenstrual dysphoric disorder: Definitions and diagnosis. Psychoneuroendocrinology, 28, 25-37.
19. Freeman, E. W., DeRubeis, R. J., & Rickels, K. (1996). Reliability and validity of a daily diary for premenstrual syndrome. Psychiatry Research, 65, 97-106.
20. Freeman, E. W., & Rickels, K. (1999). Characteristics of placebo responses in medical treatment of premenstrual syndrome. American Journal of Psychiatry, 156, 1403-1408.
21. Freeman, E. W., Rickels, K., Sondheimer, S. J., & Polansky, M. (1995). A double-blind trial of oral progesterone, alprazolam, and placebo in treatment of severe premenstrual syndrome. JAMA, 274, 51-57.
22. Freeman, E. W., Rickels, K., Sondheimer, S. J., & Polansky, M. (1999). Differential response to antidepressants in women with premenstrual syndrome/premenstrual dysphoric disorder: A randomized controlled trial. Archives of General Psychiatry, 56, 932-939.
23. Freeman, E. W., Rickels, K., Yonkers, K. A., Kunz, N. R., McPherson, M., & Upton, G. V. (2001). Venlafaxine in the treatment of premenstrual dysphoric disorder. Obstetrics and Gynecology, 98, 737-744.
24. Glass, G. V., McGaw, B., & Smith, M. L. (1981). Meta-analysis in social research. Beverly Hills, CA: Sage.
25. Halbreich, U. (2008). Selective serotonin reuptake inhibitors and initial oral contraceptives for the treatment of PMDD: Effective but not enough. CNS Spectrums, 13, 569-572.
26. Halbreich, U., Backstrom, T., Eriksson, E., O'Brien, S., Calil, H., Ceskova, E., et al. (2007). Clinical diagnostic criteria for premenstrual syndrome and guidelines for their quantification for research studies. Gynecological Endocrinology, 23, 123-130.
27. Halbreich, U., Bergeron, R., Yonkers, K. A., Freeman, E., Stout, A. L., & Cohen, L. (2002). Efficacy of intermittent, luteal phase sertraline treatment of premenstrual dysphoric disorder. Obstetrics and Gynecology, 100, 1219-1229.
28. Halbreich, U., Bornstein, J., Pearlstein, T., & Kahn, L. S. (2003). The prevalence, impairment, impact and burden of premenstrual dysphoric disorder (PMS, PMDD). Psychoneuroendocrinology, 28(Suppl. 3), 1-23.
29. Hedges, L. V. (1981). Distribution theory for Glass's estimator of effect size and related estimators. Journal of Educational Statistics, 7, 107-128.
30. Hedges, L. V., & Olkin, I. (1985). Statistical methods for metaanalysis. Orlando: Academic Press.
31. Hicks, S. M., Walker, A. F., Gallagher, J., Middleton, R. W., & Wright, J. M. (2004). The significance of "nonsignificance" in randomized controlled studies: A discussion inspired by a double-blinded study on St. John's wort (Hypericum perforatum L.) for premenstrual symptoms. Journal of Alternative and Complementary Medicine, 10, 925-932.
32. Hunter, M. S., Ussher, J. M., Browne, S. J., Cariss, M., Jelley, R., & Katz, M. (2002). A randomized comparison of psychological (cognitive behavior therapy), medical (fluoxetine) and combined treatment for womenwith premenstrual dysphoric disorder. Journal of Psychosomatic Obstetrics and Gynaecology, 23, 193-199.
33. Hunter, M. S., Ussher, J. M., Cariss, M., Browne, S., Jelley, R., & Katz, M. (2002). Medical (fluoxetine) and psychological (cognitive-behavioural therapy) treatment for premenstrual dysphoric disorder: A study of treatment processes. Journal of Psychosomatic Research, 53, 811-817.
34. Jadad, A. R., Moore, R. A., Carroll, D., Jenkinson, C., Reynolds, J. M., Gavaghan, D. J., et al. (1996). Assessing the quality of reports of randomized clinical trials: Is blinding necessary? Controlled Clinical Trials, 17, 1-12.
35. Kirkby, R. J. (1994). Changes in premenstrual symptoms and irrational thinking following cognitive behavioral coping skills training. Journal of Consulting and Clinical Psychology, 5, 1026-1032.
36. Kornstein, S. G., Pearlstein, T. B., Fayyad, R., Farfel, G. M., & Gillespie, J. A. (2006). Low-dose sertraline in the treatment of moderate-to-severe premenstrual syndrome: Efficacy of 3 dosing strategies. Journal of Clinical Psychiatry, 67, 1624-1632.
37. Landén, M., Nissbrandt, H., Allgulander, C., Sörvik, K., Ysander, C., & Eriksson, E. (2007). Placebo-controlled trial comparing intermittent and continuous paroxetine in premenstrual dysphoric disorder. Neuropsychopharmacology, 32, 153-161.
38. Leichsenring, F., Rabung, S., & Leibing, E. (2004). The efficacy of short-term psychodynamic psychotherapy in specific psychiatric disorders. Archives of General Psychiatry, 61, 1208-1216.
39. Lipsey, M. W., & Wilson, D. B. (1993). The efficacy of psychological, educational, and behavioral treatment: Confirmation from meta-analysis. American Psychologist, 48, 1181-1209.
40. Lipsey, M. W., & Wilson, D. B. (2001). Practical meta-analysis. Thousand Oaks, CA: Sage.
41. Margolis, A. (1986). The use of a cognitive restructuring intervention in the treatment of premenstrual syndrome: A controlled study (Doctoral dissertation, Ohio University, Ohio, 1985). Dissertation Abstracts International, 47/01-B, 381-716.
42. Microsoft Office Excel 2003 [Computer software]. (2003). Redmond, WA: Microsoft Corporation.
43. Moos, R. H. (1986). The development of a menstrual distress questionnaire. Psychosomatic Medicine, 30, 853-867.
44. Morse, G. (1999). Positively reframing perceptions of the menstrual cycle among women with premenstrual syndrome. Journal of Obstetric, Gynecologic, and Neonatal Nursing, 28, 165-174.
45. Orwin, R. G. (1983). A fail-safe N for effect size in meta-analysis. Journal of Educational Statistics, 8, 157-159.
46. Pearlstein, T. B., Bellew, K. M., Endicott, J., & Steiner, M. (2005). Paroxetine controlled release for premenstrual dysphoric disorder: Remission analysis following a randomized, double-blind, placebo-controlled trial. Primary Care Companion to the Journal of Clinical Psychiatry, 7, 53-60.
47. Pearlstein, T. B., Stone, A. B., Lund, S. A., Scheft, H., Zlotnick, C., & Brown, W. A. (1997). Comparison of fluoxetine, bupropion, and placebo in the treatment of premenstrual dysphoric disorder. Journal of Clinical Psychopharmacology, 17, 261-266.
48. Pearlstein, T. B., Yonkers, K., Fayyad, R., & Gillespie, J. (2005). Pretreatment pattern of symptom expression in premenstrual dysphoric disorder. Journal of Affective Disorders, 85, 275-282.
49. Shah, N. R., Jones, J. B., Aperi, J., Shemtov, R., Karne, A., & Borenstein, J. (2008). Selective serotonin reuptake inhibitors for premenstrual syndrome and premenstrual dysphoric disorder. A meta-analysis. Obstetrics and Gynecology, 5, 1175-1182.
50. Sheenan, D. V. (1983). The anxiety disease. New York: Scribner.
51. Steiner, M., Ravindran, A. V., LeMelledo, J. M., Carter, D., Huang, J. O., Anonychuk, A. M., et al. (2008). Luteal phase administration of paroxetine for the treatment of premenstrual dysphoric disorder: A randomized, double-blind, placebo-controlled trial in Canadian women. Journal of Clinical Psychiatry, 69, 991-998.
52. Steiner, M., Romano, S. J., Babcock, S., Dillon, J., Shuler, C., Berger, C., et al. (2001). The efficacy of fluoxetine in improving physical symptoms associated with premenstrual dysphoric disorder. BJOG International Journal of Obstetrics and Gynaecology, 108, 462-468.
53. Steiner, M., Steinberg, S., Stewart, D., Carter, D., Berger, C., Reid, R., et al. (1995). Fluoxetine in the treatment of premenstrual dysphoria. New England Journal of Medicine, 332, 1529-1534.
54. Stone, A. B., Pearlstein, T. B., & Brown, W. A. (1991). Fluoxetine in the treatment of late luteal phase dysphoric disorder. Journal of Clinical Psychiatry, 52, 290-293.
55. Taylor, D. (1999). Effectiveness of professional peer group treatment: Symptom management for women with PMS. Research in Nursing and Health, 22, 496-511.
56. Thomson, A. B., & Page, L. A. (2007). Psychotherapies for hypochondriasis. Cochrane Database of Systematic Reviews 2007, Art. No.: CD006520. doi:10.1002/14651858.CD006520.pub2.
57. Van Ree, J. M., Schagen Van Leeuwen, J. H., Koppeschaar, H. P., & Te Velde, E. R. (2005). Unexpected placebo response in premenstrual dysphoric disorder: Implication of endogenous opioids. Psychopharmacology, 182, 318-319.
58. Weiss, C. R. (1988). Cognitive-behavioral group therapy for the treatment of premenstrual distress (Doctoral dissertation, State University of New York at Buffalo, New York, 1988). Dissertation Abstracts International, 49/06-B, 2389-2658.
59. Wilson, D. B. (2005). Meta-analysis macros for SAS, SPSS, and Stata. Retrieved January 22, 2010, from http://mason.gmu.edu/ dwilsonb/ma.html.
60. Wittchen, H. U., Becker, E., Lieb, R., & Krause, P. (2002). Prevalence, incidence and stability of premenstrual dysphoric disorder in the community. Psychological Medicine, 32, 119-132.
61. Yonkers, K. A., Halbreich, U., & Freeman, E. (1997). Symptomatic improvement of premenstrual dysphoric disorder with sertraline treatment. A randomized controlled trial. JAMA, 278, 983-988.
62. Yonkers, K. A., Holthausen, G. A., Poschman, K., & Howell, H. B. (2006). Symptom-onset treatment for women with premenstrual dysphoric disorder. Journal of Clinical Psychopharmacology, 26, 198-202.